Document is current
Any future updates will be listed below
-
Authors
Bartolomé, Blanca https://orcid.org/0000-0001-5423-9939
Torres, Manuel https://orcid.org/0009-0004-0471-8826
González-Álamos, María https://orcid.org/0000-0002-5769-4299
Vivanco, Luis https://orcid.org/0000-0003-3747-6240
-
Funding
Funding for this research was provided by:
POCTEFA (EFA060/01-CO-BIEN)
POCTEFA (EFA060/01-CO-BIEN)
POCTEFA (EFA060/01-CO-BIEN)
POCTEFA (EFA060/01-CO-BIEN)
- License Information
-
More Information
Article History
Received: 31 October 2025
Accepted: 4 February 2026
First Online: 11 February 2026
Declarations
:
: The study received approval from the Ethics Committee for Research with Medicines of La Rioja (Comité de Ética en Investigación con Medicamentos de La Rioja, CEImLAR; Ref. CEImLAR PI-795, October 17th, 2024). CEImLAR is the ethics committee affiliated with the Health Department (Consejería de Salud) of the Government of La Rioja, and is responsible for the ethical evaluation of all studies involving human participants conducted within this autonomous community in Spain. Written informed consent was obtained from all participants prior to their inclusion in the study, in accordance with Real Decreto 1090/2015 (Spain) and the principles of the Declaration of Helsinki. All participants were also informed that they could withdraw from the study at any time.
: Not Applicable.
: The authors declare no competing interests.
